BMD Z score (lumbar spine) · women with low bone mass and β‐thalassaemia
1 finding from 1 review
BMD Z score (wrist) · women with low bone mass and β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of fractures · women with low bone mass and β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mobility · women with low bone mass and β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (back pain VAS score in cm) · women with low bone mass and β‐thalassaemia
1 finding from 1 review
Adverse effects of treatment · women with low bone mass and β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of fractures · adults with β‐thalassaemia and osteoporosis
1 finding from 1 review
Mobility · adults with β‐thalassaemia and osteoporosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (change in mean back pain) · adults with β‐thalassaemia and osteoporosis
1 finding from 1 review
Adverse effects of treatment · adults with β‐thalassaemia and osteoporosis
It is very uncertain whether summary of findings – bisphosphonates changes adverse effects of treatment compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Perioperative mortality · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes perioperative mortality Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Serious adverse events Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes serious adverse events Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Postoperative transfusion Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes postoperative transfusion Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Reoperation Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes reoperation Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Postoperative bile leak Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes postoperative bile leak Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · people (aged 12 years and over) with drug‐resistant focal epilepsy
Perampanel add‐on leads to higher ≥ 50% reduction in seizure frequency compared with placebo (high certainty).
1 finding from 1 review
Seizure freedom · people (aged 12 years and over) with drug‐resistant focal epilepsy
Perampanel add‐on may leads to higher seizure freedom compared with placebo (low certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · people (aged 12 years and over) with drug‐resistant focal epilepsy
Perampanel add‐on may leads to higher treatment withdrawal due to any reason compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people (aged 12 years and over) with drug‐resistant focal epilepsy
Perampanel add‐on may leads to higher treatment withdrawal due to adverse effects compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants who experienced ≥ 1 adverse effect · people (aged 12 years and over) with drug‐resistant focal epilepsy
Perampanel add‐on leads to higher proportion of participants who experienced ≥ 1 adverse effect compared with placebo (high certainty).
1 finding from 1 review